Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor
about
TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traitsTherapeutic potential of tyrosine kinase 2 in autoimmunity.Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.Global connectivity of hub residues in Oncoprotein structures encodes genetic factors dictating personalized drug response to targeted Cancer therapy.
P2860
Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Enabling structure-based drug ...... lizing aminoindazole inhibitor
@ast
Enabling structure-based drug ...... lizing aminoindazole inhibitor
@en
Enabling structure-based drug ...... lizing aminoindazole inhibitor
@nl
type
label
Enabling structure-based drug ...... lizing aminoindazole inhibitor
@ast
Enabling structure-based drug ...... lizing aminoindazole inhibitor
@en
Enabling structure-based drug ...... lizing aminoindazole inhibitor
@nl
prefLabel
Enabling structure-based drug ...... lizing aminoindazole inhibitor
@ast
Enabling structure-based drug ...... lizing aminoindazole inhibitor
@en
Enabling structure-based drug ...... lizing aminoindazole inhibitor
@nl
P2093
P2860
P356
P1476
Enabling structure-based drug ...... lizing aminoindazole inhibitor
@en
P2093
Andrew Burchat
David Banach
Doug Marcotte
Eric R Goedken
Gary Overmeyer
Jeffrey Voss
Kevin Woller
Maria A Argiriadi
Medha Tomlinson
P2860
P2888
P356
10.1186/1472-6807-12-22
P577
2012-09-20T00:00:00Z
P5875
P6179
1044141515